Outlook Therapeutics announced financial results for fiscal year 2025, showcasing net loss reduction and revenue generation.
The company reported a net loss of $62.4 million, compared to $75.4 million in the prior year, along with $1.4 million in revenue.
Fiscal 2025 marked the initial sales of LYTENAVA™ in Germany and the UK, with a focus on market access and pricing strategies.
Financial Performance
Net loss decreased to $62.4 million from $75.4 million in the prior year, with $1.4 million in revenue for fiscal year 2025.
Market Expansion
LYTENAVA™ acceptance into the UK tender framework and initiation of a real-world data study in Germany aim to boost unit sales.
Expense Management
Overall expenses in fiscal 2025 decreased by $4.6 million compared to the previous year, driven by reduced R&D costs.
Cash Position
As of September 30, 2025, Outlook Therapeutics had $8.1 million in cash and cash equivalents, excluding $14.9 million in net proceeds post-September.
- The strategic market access efforts in the UK and Germany led to positive sales growth for LYTENAVA™ during fiscal 2025.
- Expense reductions and R&D efficiency contributed to a stronger financial position for Outlook Therapeutics by the end of the year.
Outlook Therapeutics' fiscal year 2025 was marked by improved financial performance, market expansion initiatives, and a focus on positioning for future success in the U.S. and international markets.